An Open-Label, Intravenous To Oral Switch, Multiple Dose, Multi-Center Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Voriconazole In Hospitalized Children Aged 2 - <12 Years Who Require Treatment For The Prevention Of Systemic Fungal Infection
2 Years
11 Years
Both
Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Neutropenia, Sarcoma
Trial Information
An Open-Label, Intravenous To Oral Switch, Multiple Dose, Multi-Center Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Voriconazole In Hospitalized Children Aged 2 - <12 Years Who Require Treatment For The Prevention Of Systemic Fungal Infection
OBJECTIVES:
- Determine the pharmacokinetics of voriconazole administered IV and orally for the
prevention of systemic fungal infection in pediatric patients with neutropenia after
chemotherapy.
- Determine the safety and tolerability of this drug in these patients.
OUTLINE: This is a pilot, open-label, multicenter study. Patients are stratified according
to age (2 to 5 vs 6 to 11).
Within 48 hours after completion of chemotherapy, patients begin prophylactic therapy:
- Cohort 1 (the first 18 patients, 9 per stratum): Patients receive voriconazole IV over
80-160 minutes twice daily on days 1-8 and oral voriconazole* twice daily beginning on
day 9.
Depending on the results of the interim pharmacokinetic analysis, the last 18 patients
entered on the study receive 1 of the following regimens:
- Cohort 2A:Patients receive voriconazole as in cohort 1 at a higher dose.
- Cohort 2B: Patients receive voriconazole IV over 80-160 minutes twice daily on days 1-4
and oral voriconazole* twice daily beginning on day 5.
NOTE: *Patients who are unable to tolerate oral medication may continue receiving IV
medication until day 20.
In all cohorts, treatment continues until blood counts recover or day 30 in the absence of
unacceptable toxicity or progression of infection.
Patients are followed at 30 days and at 12 months.
PROJECTED ACCRUAL: A total of 49 patients (approximately 24 per stratum) were accrued for
this study within 1 year.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Expected to develop neutropenia (absolute neutrophil count less than 500/mm^3)
lasting for more than 10 days after chemotherapy for 1 of the following conditions:
- Leukemia
- Lymphoma
- Aplastic anemia
- Preparation for a bone marrow or stem cell transplantation
- Requiring treatment for the prevention of systemic fungal infection
PATIENT CHARACTERISTICS:
Age
- 2 to 11
Performance status
- Not specified
Life expectancy
- More than 3 months
Hematopoietic
- See Disease Characteristics
Hepatic
- AST and ALT no greater than 5 times upper limit of normal (ULN)
- Bilirubin no greater than 5 times ULN
Renal
- Creatinine clearance at least 30 mL/min
Cardiovascular
- No cardiac arrhythmia
Other
- Not pregnant or nursing
- Negative pregnancy test
- No severe hypokalemia (potassium less than 3.2 mmol/L)
- No prior hypersensitivity to or severe intolerance of azole antifungal agents
- No other concurrent condition that would preclude study therapy
PRIOR CONCURRENT THERAPY:
Biologic therapy
- See Disease Characteristics
Chemotherapy
- See Disease Characteristics
Endocrine therapy
- Not specified
Radiotherapy
- Not specified
Surgery
- Not specified
Other
- At least 24 hours since prior use of any of the following:
- Terfenadine
- Pimozide
- Quinidine
- Astemizole
- Cisapride
- Omeprazole
- More than 14 days since prior use of any of the following:
- Rifampin
- Rifabutin
- Carbamazepine
- Phenytoin
- Nevirapine
- Long-acting barbiturates
- No prior sirolimus
- No prior enrollment on this study
- No concurrent use of any of the following:
- Terfenadine
- Pimozide
- Quinidine
- Astemizole
- Cisapride
- Omeprazole
- No other concurrent investigational drugs except any of the following:
- Drugs used as treatment for cancer
- Antiretroviral agents
- Drugs used for the treatment of any AIDS-defining opportunistic infections
- No concurrent enrollment in investigational anticancer drug trials that exclude the
use of other investigational agents
Type of Study:
Interventional
Study Design:
Masking: Open Label, Primary Purpose: Supportive Care
Principal Investigator
Thomas J. Walsh, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
National Cancer Institute (NCI)
Authority:
United States: Federal Government
Study ID:
CDR0000316329
NCT ID:
NCT00066599
Start Date:
June 2003
Completion Date:
June 2004
Related Keywords:
- Kidney Cancer
- Leukemia
- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Neoplasms
- Neuroblastoma
- Neutropenia
- Sarcoma
- neutropenia
- recurrent childhood lymphoblastic lymphoma
- stage I childhood lymphoblastic lymphoma
- stage II childhood lymphoblastic lymphoma
- stage III childhood lymphoblastic lymphoma
- stage IV childhood lymphoblastic lymphoma
- recurrent childhood small noncleaved cell lymphoma
- stage I childhood small noncleaved cell lymphoma
- stage II childhood small noncleaved cell lymphoma
- stage III childhood small noncleaved cell lymphoma
- stage IV childhood small noncleaved cell lymphoma
- recurrent childhood large cell lymphoma
- stage I childhood large cell lymphoma
- stage II childhood large cell lymphoma
- stage III childhood large cell lymphoma
- stage IV childhood large cell lymphoma
- childhood acute myeloid leukemia in remission
- recurrent childhood acute myeloid leukemia
- untreated childhood acute myeloid leukemia and other myeloid malignancies
- recurrent/refractory childhood Hodgkin lymphoma
- stage I childhood Hodgkin lymphoma
- stage II childhood Hodgkin lymphoma
- stage III childhood Hodgkin lymphoma
- stage IV childhood Hodgkin lymphoma
- childhood acute promyelocytic leukemia (M3)
- previously treated childhood rhabdomyosarcoma
- recurrent Wilms tumor and other childhood kidney tumors
- recurrent childhood rhabdomyosarcoma
- childhood chronic myelogenous leukemia
- accelerated phase chronic myelogenous leukemia
- blastic phase chronic myelogenous leukemia
- chronic phase chronic myelogenous leukemia
- meningeal chronic myelogenous leukemia
- relapsing chronic myelogenous leukemia
- anaplastic large cell lymphoma
- angioimmunoblastic T-cell lymphoma
- intraocular lymphoma
- primary central nervous system non-Hodgkin lymphoma
- recurrent adult T-cell leukemia/lymphoma
- acute undifferentiated leukemia
- childhood acute lymphoblastic leukemia in remission
- recurrent childhood acute lymphoblastic leukemia
- secondary acute myeloid leukemia
- untreated childhood acute lymphoblastic leukemia
- disseminated neuroblastoma
- de novo myelodysplastic syndromes
- previously treated myelodysplastic syndromes
- secondary myelodysplastic syndromes
- stage I multiple myeloma
- stage II multiple myeloma
- stage III multiple myeloma
- refractory multiple myeloma
- stage I cutaneous T-cell non-Hodgkin lymphoma
- stage II cutaneous T-cell non-Hodgkin lymphoma
- stage III cutaneous T-cell non-Hodgkin lymphoma
- stage IV cutaneous T-cell non-Hodgkin lymphoma
- recurrent neuroblastoma
- atypical chronic myeloid leukemia, BCR-ABL1 negative
- myelodysplastic/myeloproliferative neoplasm, unclassifiable
- Neoplasms
- Carcinoma, Renal Cell
- Kidney Neoplasms
- Leukemia
- Lymphoma
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Plasmacytoma
- Mycoses
- Myelodysplastic Syndromes
- Preleukemia
- Myeloproliferative Disorders
- Neuroblastoma
- Neutropenia
- Lymphoma, Non-Hodgkin
- Sarcoma
- Myelodysplastic-Myeloproliferative Diseases
Name | Location |
|---|---|
| Children's Hospital of Philadelphia | Philadelphia, Pennsylvania 19104 |
| Duke Comprehensive Cancer Center | Durham, North Carolina 27710 |
| Ireland Cancer Center | Cleveland, Ohio 44106-5065 |
| Children's Hospital of Orange County | Orange, California 92668 |
| Children's Hospital and Health Center, San Diego | San Diego, California 92123-4282 |
| Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas | Dallas, Texas 75390-9063 |
| Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support | Bethesda, Maryland 20892-1182 |
